when were glp 1 drugs approved History of glucagon-like peptide-1 receptor agonists The first weight loss drugs

If you are planning a pregnancy, youll usually be advised to stop these medicines some time before conception and switch to treatments known to be safe in pregnancy, such as insulin

Retatrutide: A Triple Agonist with Unprecedented Efficacy Retatrutide (LY3437943) is a novel triple incretin agonist that simultaneously targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors

F., & STEP 1 Study Group (2021)

Also, as an anabolic hormone, insulin promotes fat storage, and chronic hyperinsulinemia, commonly observed in T2DM, further stimulates lipogenesis while suppressing lipolysis, thereby counteracting BW reduction

Most GLP-1 receptor agonists are given as a small injection under your skin, typically once a week